Literature DB >> 12583824

Pegylated interferon alfa-2b as treatment of patients with solid tumors.

Ronald M Bukowski.   

Abstract

Entities:  

Year:  2003        PMID： 12583824     DOI： 10.1007/s11912-003-0094-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  8 in total

1.  A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

Authors:  K L Lindsay; C Trepo; T Heintges; M L Shiffman; S C Gordon; J C Hoefs; E R Schiff; Z D Goodman; M Laughlin; R Yao; J K Albrecht
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

Review 2.  Clinical practice guidelines: renal cell carcinoma.

Authors:  R M Bukowski; A C Novick
Journal:  Cleve Clin J Med       Date:  1997       Impact factor: 2.321

3.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Authors:  R J Motzer; M Mazumdar; J Bacik; W Berg; A Amsterdam; J Ferrara
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

4.  Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

Authors:  M Talpaz; S O'Brien; E Rose; S Gupta; J Shan; J Cortes; F J Giles; S Faderl; H M Kantarjian
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

Review 5.  The role of interferon alfa in the treatment of metastatic melanoma.

Authors:  S S Legha
Journal:  Semin Oncol       Date:  1997-02       Impact factor: 4.929

6.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

Review 7.  Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.

Authors:  Ronald M Bukowski; Craig Tendler; David Cutler; Esther Rose; Mark M Laughlin; Paul Statkevich
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

8.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Authors:  J M Kirkwood; M H Strawderman; M S Ernstoff; T J Smith; E C Borden; R H Blum
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.